Back to search results

Long-Term Follow-up for Stem Cell, Cellular, or Gene Therapy

This observational study is for people who have received a hematopoietic stem cell transplant (HCT), cellular therapy, or gene therapy. Researchers want to understand the long-term effects of these treatments and how they impact your health over time. They will collect information, blood, and tissue samples to learn about potential late complications. The goal is to improve future treatments and care for individuals who undergo these therapies. You may be able to join if you are at least 4 years old and survived at least one year after your treatment. This study aims to understand the basic characteristics of the patient population, with data collected until death.

Study design
This is an observational study with a planned enrollment of 2000 participants. It is not testing a specific intervention but rather observing long-term outcomes.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed until death to collect basic characteristics of the patient population.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03000244

Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy

Recruiting
Not specifiedAges 4+Observational
National Cancer Institute (NCI)
~2,000 participants
Updated 2026-08-28 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Basic characteristics of the patient population
Measured over at death

Conditions

Cellular Immunotherapy, Adoptive
Genetic Therapy
Tissue Donors
Hematopoietic Stem Cell Transplantation

Explore related trials

Cellular TherapyGene TherapyHematopoietic Cell Transplantation

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Najla El Jurdi, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Danielle F Pinkiert, R.N.
[email protected]
(240) 858-7566
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals who underwent HCT or received cellular or gene therapy for any indication (malignant or non-malignant) and are surviving one year or more from the date of therapy
Age \>= 4 years
Ability of individual or individual s Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document
Individuals will need to have a primary physician within the US (primary care, oncologist, hematologist, etc.) that will provide continued comprehensive care for the duration of participation in the study. PI may allow for established medical providers to be located outside of the US.
Related stem cell donors of patients meeting the above criteria as a donor of hematopoietic progenitor and stem cells or leukocytes
Age \>= 4years
Ability of patient or patient s Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document
Parents/guardians of minors enrolled on the study who have undergone HCT
Willingness to complete surveys about the minor that underwent HCT

Exclusion

Individuals with active disease relapse or new hematologic malignancy including post-transplant lymphoproliferative disorder (PTLD) are excluded from protocol enrollment.

What this trial measures

  • Basic characteristics of the patient populationat death

    Survival